| 1 |
邓仁芳，曾 月，潘 越，等. 驱动基因阳性非小细胞肺癌免疫治疗进展[J]. 中国肺癌杂志，2022, 25(3): 201-206.
|
| 2 |
周彩存，王 洁，步 宏，等. 中国非小细胞肺癌免疫检查点抑制剂治疗专家共识(2020年版)[J]. 中国肺癌杂志，2021, 24(4): 217-235.
|
| 3 |
Masuda K, Horinouchi H, Tanaka M, et al. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression[J]. J Cancer Res Clin Oncol, 2021, 147(1): 245-251.
|
| 4 |
李一然，王玉秀，朱 研，等. 基于GEO数据库分析影响纳武单抗及派姆单抗治疗非小细胞肺癌疗效的差异基因[J/CD]. 中华肺部疾病杂志(电子版), 2023, 16(1): 20-25.
|
| 5 |
Minor M, Alcedo KP, Battaglia RA, et al. Cell type-and tissue-specific functions of ecto-5′-nucleotidase (CD73)[J]. Am J Physiol Cell Physiol, 2019, 317(6): C1079-C1092.
|
| 6 |
Ghalamfarsa G, Kazemi MH, Raoofi Mohseni S, et al.CD73as a potential opportunity for cancer immunotherapy[J]. Expert Opin Ther Targets, 2019, 23(2): 127-142.
|
| 7 |
Goswami S, Walle T, Cornish AE, et al. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma[J]. Nat Med, 2020, 26(1): 39-46.
|
| 8 |
Ghalamfarsa G, Rastegari A, Atyabi F, et al. Anti-angiogenic effects of CD73-specific siRNA-loaded nanoparticlesin breast cancer-bearing mice[J]. J Cell Physiol, 2018, 233(10): 7165-7177.
|
| 9 |
Liu XH, Wu XR, Lan N, et al. CD73 promotes colitis-associated tumorigenesis in mice[J]. Oncol Lett, 2020, 20(2): 1221-1230.
|
| 10 |
马彦娥，苏虎艳，王倩如，等. 非小细胞肺癌组织中miR-30a和CD73的表达水平与预后相关性分析[J]. 现代检验医学杂志，2022, 37(3): 73-78.
|
| 11 |
Morse B, Jeong D, Ihnat G, et al. Pearls and pitfalls of response evaluation criteria in solid tumors (RECIST) v1.1 non-target lesion assessment[J]. Abdom Radiol (NY), 2019, 44(2): 766-774.
|
| 12 |
Jiang X, Wu X, Xiao Y, et al. The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy[J]. Front Immunol, 2023, 14: 1110325.
|
| 13 |
Yang R, Elsaadi S, Misund K, et al. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade[J]. J Immunother Cancer, 2020, 8(1): e000610.
|
| 14 |
Ma XL, Shen MN, Hu B, et al. CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis[J]. J Hematol Oncol, 2019, 12: 37-53.
|
| 15 |
Xu Z, Gu C, Yao X, et al. CD73 promotes tumor metastasis by modulating RICS/RhoA signaling and EMT in gastric cancer[J]. Cell Death Dis, 2020, 11(3): 202-216.
|
| 16 |
Yu X, Liu W, Wang Z, et al. CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms[J]. Cancer Lett, 2021, 519: 289-303.
|
| 17 |
Snider NT, Altshuler PJ, Wan S, et al. Alternative splicing of human NT5E in cirrhosis and hepatocellular carcinoma produces a negative regulator of ecto-5′-nucleotidase (CD73)[J]. Mol Biol Celll, 2014, 25(25): 4024-4033.
|
| 18 |
Gao Z, Wang H, Lin F, et al. CD73 promotes proliferation and migration of human cervical cancer cells independent of its enzyme activity[J]. BMC Cancer, 2017, 17(1): 135-142.
|
| 19 |
Wu R, Chen Y, Li F, et al. Effects of CD73 on human colorectal cancer cell growth in vivo and in vitro[J]. Oncol Rep, 2016, 35(3): 1750-1756.
|
| 20 |
肖文华，孙荣丽. CD39/CD73及其介导的腺苷信号通路在肺癌免疫调控中的作用及研究进展[J]. 癌症进展，2022, 20(1): 12-17.
|
| 21 |
Pacheco JM, Schenk EL. CD73 and Adenosine receptor signaling as a potential therapeutic target in EGFR-mutated NSCLC[J]. J Thorac Oncol, 2021, 16(4): 509-511.
|
| 22 |
Gardani CFF, Cappellari AR, de Souza JB, et al. Hydrolysis of ATP, ADP, and AMP is increased in blood plasma of prostate cancer patients[J]. Purinergic Signal, 2019, 15: 95-105.
|
| 23 |
de Lourdes Mora-García M, López-Cisneros S, Gutiérrez-Serrano V, et al. HPV-16 infection is associated with a high content of CD39 and CD73 ectonucleotidases in cervical samples from patients with CIN-1[J]. Mediators Inflamm, 2019, 2019: 1-13.
|
| 24 |
Messaoudi N, Cousineau I, Arslanian E, et al. Prognostic value of CD73 expression in resected colorectal cancer liver metastasis[J]. Oncoimmunology, 2020, 9(1): 1746138.
|
| 25 |
Le X, Negrao MV, Reuben A, et al.Characterization of the immune landscape of EGFR-mutantNSCLC identifiesCD73/adenosine pathwayasa potential therapeutic target[J]. J Thorac Oncol, 2021, 16(4): 583-600.
|
| 26 |
Griesing S, Liao BC, Yang JC. CD73 is regulated by the EGFR-ERK signaling pathway in non-small cell lung cancer[J]. Anticancer Res, 2021, 41(3): 1231-1242.
|
| 27 |
Turiello R, Capone M, Giannarelli D, et al. Serum CD73 is a prognostic factor in patients with metastaticmelanomaand is associated with response to anti-PD-1 therapy[J]. J Immunother Cancer, 2020, 8(2): e001689.
|
| 28 |
付光明，刘 平，吴 芳，等. 一代EGFR-TKIs治疗后进展的晚期NSCLC外周血T790M突变特征[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(2): 169-173.
|
| 29 |
唐心蔚，高天敏，张君国. 自噬在非小细胞肺癌EGFR-TKI耐药中作用的研究进展[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(2): 250-252.
|
| 30 |
Tu E, McGlinchey K, Wang J, et al. Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC[J]. JCI Insight, 2022, 7(3): e142843.
|
| 31 |
Kim M, Min YK, Jang J, et al. Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer[J]. J Immunother Cancer, 2021, 9(7): e002503.
|
| 32 |
Monteiro I, Vigano S, Faouzi M, et al. CD73 expression and clinical significance in human metastaticmelanoma[J]. Oncotarget, 2018, 9(42): 26659-26669.
|